Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center
Frontiers in Cardiovascular Medicine · 02.07.2024 · 11
DOI: 10.3389/fcvm.2024.1379199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 02.07.2024. Verfasst von Marina Pieri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Impella 5.0 and 5.5 are promising low-invasive left ventricle (LV) temporary mechanical circulatory supports (tMCS) for cardiogenic shock due to LV mechanical unloading and are paired with powerful hemodynamic support. This study aimed to analyze data and destinies of patients supported with Impella 5.0/5.5 at a national referral center for cardiogenic shock and to assess the parameters associated with myocardial recovery and successful weaning.
Methods
A single-center observational study was conducted on all patients treated with Impella 5.0 or 5.5 from March 2018 to July 2023.
Results
A total of 59 patients underwent Impella 5.0/5.5 implantation due to profound cardiogenic shock, with acute myocardial infarction being the most frequent cause of shock (42 patients, 71%). The median duration of Impella support was 13 days (maximum duration of 52 days). Axillary cannulation was feasible in almost all patients, and 36% were mobilized during support. A total of 44 patients (75%) survived to the next therapy/recovery: 21 patients experienced recovery and 15 and 8 were bridged to long-term LVAD and heart transplantation, respectively. The global survival rate was 66%. The predictors of native heart recovery at multivariate analysis were the number of days on tMCS before upgrade to Impella 5.0/5.5 [hazard ratio (HR) 0.68 (0.51–9) p = 0.0068] and improvement of LVEF within the first 7–10 days of support [HR 4.72 (1.34–16.7), p = 0.016].
Conclusions
Transcatheter systems such as Impella 5.0/5.5 revolutionized the field of tMCS. Myocardial recovery is the primary clinical target. Its prognostication and promotion are key to ensure the most proficuous course for each patient from cardiogenic shock to long-term event-free survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
- School of Medicine, Brescia University School of Medicine, Brescia, Italy.
- Department of Cardiac Surgery, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Zitieren
APA
Pieri, M., Ortalda, A., Altizio, S., Bertoglio, L., Nardelli, P., Fominskiy, E., Lapenna, E., Ajello, S., & Scandroglio, A. M. (2024). Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1379199
Vancouver
Pieri M, Ortalda A, Altizio S, Bertoglio L, Nardelli P, Fominskiy E, et al. Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center. Frontiers in Cardiovascular Medicine. 2024;11. doi:10.3389/fcvm.2024.1379199
BibTeX
@article{Pieri2024,
author = {Pieri, Marina and Ortalda, Alessandro and Altizio, Savino and Bertoglio, Luca and Nardelli, Pasquale and Fominskiy, Evgeny and Lapenna, Elisabetta and Ajello, Silvia and Scandroglio, Anna Mara},
title = {Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center},
journal = {Frontiers in Cardiovascular Medicine},
year = {2024},
volume = {11},
doi = {10.3389/fcvm.2024.1379199}
}
EUVIMED